Name: AZD1208
Price: 223.00 USD

- Overview
  - Please contact us at for specific academic pricing.
    
    Background
    
    IC50: 0.4 nM for Pim-1, 5.0 nM for Pim-2, and 1.9 nM for Pim-3
    Upregulation of Pim kinases has been observed in several types of leukemias and lymphomas. Pim-1, -2, and -3 promote cell proliferation and survival downstream of cytokine and growth factor signaling pathways. AZD1208 is a potent, highly selective, and orally available Pim kinase inhibitor.
    In vitro: AZD1208 inhibited the growth of 5 of 14 acute myeloid leukemia (AML) cell lines tested. In MOLM-16 cells, AZD1208 also causes cell cycle arrest and apoptosis, accompanied by a dose-dependent reduction in phosphorylation of Bcl-2 antagonist of cell death [1].
    In vivo: AZD1208 inhibits the growth of KG-1a and MOLM-16 xenograft tumors in vivo with a clear PK/PD relationship. Treatment with 10 mg/kg or 30 mg/kg of AZD1208 led to an 89% tumor growth inhibition or slight regression, respectively [1].
    Clinical trials: AZD1208 is in Phase I trials evaluating the safety and tolerability profile and to determine the maximum tolerated dose (MTD). There are two ongoing trials where AZD1208 has been orally administered in AML and solid tumor (of all types) patients
- Properties
  - Alternative Name
    
    AZD 1208;AZD-1208; (5E)-5-[[2-[(3R)-3-aminopiperidin-1-yl]-3-phenylphenyl]methylidene]-1,3-thiazolidine-2,4-dione
    
    CAS Number
    
    1204144-28-4
    
    Molecular Formula
    
    C21H21N3O2S
    
    Molecular Weight
    
    379.48
    
    Appearance
    
    A solid
    
    Purity
    
    99.58%
    
    Solubility
    
    insoluble in EtOH; insoluble in H2O; ≥18.95 mg/mL in DMSO
    
    Storage
    
    Store at -20°C
    
    * For Research Use Only

We Also Recommend

A-769662

$212

BI 2536

$300

Doxorubicin

$406

Doxorubicin

$188

AZD1208

AZD1208

Background

We Also Recommend

A-769662

BI 2536

Doxorubicin

Doxorubicin